Container/closure integrity may replace sterility testing in stability programs -- FDA draft guidance.
CONTAINER/CLOSURE INTEGRITY TESTING MAY REPLACE STERILITY TESTING in stability protocols for sterile drugs, biologics, and medical devices, FDA says in a draft guidance. FDA released the draft "Guidance for Industry: Container and Closure Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products" on Jan. 28. Comments on the draft are due by March 30.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth